PPTA Twitter

PlasmaProteins
PlasmaProteins . @DonCoppo — donors definitely deserve our gratitude for the dedication they show in supporting people living with rare, serious, & chronic diseases. With our friends at @HIYDglobal , we all agree #PlasmaDonorsSaveLives ! twitter.com/DonCoppo/status/1121060045888868358
1 day ago.
PlasmaProteins
PlasmaProteins It’s important to understand that #plasma used to manufacture #plasmaprotein therapies is intrinsically different from blood components used for transfusion. Differences include the way that plasma is collected & the complexities of the production process. bit.ly/2Qo4bsI
1 day ago.

PPTA Recognizes World PI Week: April 22 - 29, 2014

The Plasma Protein Therapeutics Association (PPTA) stands together with the global primary immunodeficiency disease (PID) community to promote the 4th annual World PI Week, a global campaign aimed to raise awareness and improve diagnosis and treatment of PID.

Under the slogan Test. Diagnose. Treat., World PI week unites, empowers and engages all global stakeholders in the primary immunodeficiency (PI) cause. Patients, nurses, physicians, scientists, allied health professionals, and industry will together advocate for testing, optimal care and the best possible treatment for a disease that although classified as rare, affects more than six million people1 worldwide, with no gender, age or geographical boundaries.

PI diseases occur in persons born with an immune system that is either absent or deficient in its ability to function. PI often present in the form of "common" infections, sometimes leading physicians to treat the infections while missing the underlying cause, allowing the illnesses to reoccur, and leaving the patient vulnerable to vital organ damage, physical disability, or even death.

With early diagnosis, proper care and optimal treatment, the disease is manageable and can save patients from lifelong disabilities, unnecessary vaccinations and lengthy hospital visits. Detecting the disease early can improve patients’ conditions offering them all the opportunity to live full and rewarding lives.

Patients with PIDs are often deficient in immunoglobulins (antibodies) needed to fight infections. Immunoglobulin therapies made from the gift of human plasma from thousands of donors and manufactured to the highest standards of safety and efficacy enhance the quality of life and the lifespan of these patients. Jan M. Bult, PPTA President and CEO said, “PPTA is proud to represent the manufacturers of these therapies who continue to strive to make new products available to further improve the lives of patients.”


1Ahmed Aziz Bousfiha & Leïla Jeddane & Fatima Ailal & Ibtihal Benhsaien & Nizar Mahlaoui & Jean-Laurent Casanova & Laurent Abel, Primary Immunodeficiency Diseases Worldwide: More Common than Generally Thought, Journal of Clinical Immunology 2013;33: 1-7

Copyright © 2018 PPTA. All rights reserved. (202) 789-3100